However, we found that Nectin-4 is also widely expressed in cervical cancer; Sacituzumab Govitecan is the world’s first and only approved ADC drug targeting Trop-2 for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (Wahby et al., 2021), and the target Trop-2 is also widely expressed in endometrial cancer, ovarian cancer, and cervical cancer; Trastuzumab Deruxtecan also has shown promising activity in various types of late stage solid tumors with ERBB2 expression, including traditionally difficult to treat malignant tumors (AACR, 2023). This evidence concerns the gene NECTIN4 and endometrial cancer.